Combination of polymyxin B and meropenem eradicates persister cells from Acinetobacter baumannii strains in exponential growth

References

1. Kaye KS, Pogue JM. Infections caused by resistant Gram-negative bacteria: epidemiology and management. Pharmacotherapy 2015; 35:949–962 [View Article][PubMed]
   [Google Scholar]
2. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014; 33:1311–1322 [View Article][PubMed]
   [Google Scholar]
3. Hagihara M, Housman ST, Nicolau DP, Kuti JL. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2014; 58:874–879 [View Article][PubMed]
   [Google Scholar]
4. Rigatto MH, Vieira FJ, Antochevis LC, Behle TF, Lopes NT et al. Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically Ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2015; 59:6575–6580 [View Article][PubMed]
   [Google Scholar]
5. Fauvart M, de Groote VN, Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol 2011; 60:699–709 [View Article][PubMed]
   [Google Scholar]
6. Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 2010; 192:6191–6199 [View Article][PubMed]
   [Google Scholar]
7. Lewis K. Persister cells. Annu Rev Microbiol 2010; 64:357–372 [View Article][PubMed]
   [Google Scholar]
8. Barth VC, Rodrigues BÁ, Bonatto GD, Gallo SW, Pagnussatti VE et al. Heterogeneous persister cells formation in Acinetobacter baumannii. PLoS One 2013; 8:e84361 [View Article][PubMed]
   [Google Scholar]
9. Day T. Interpreting phenotypic antibiotic tolerance and persister cells as evolution via epigenetic inheritance. Mol Ecol 2016; 25:1869–1882 [View Article][PubMed]
   [Google Scholar]
10. Lewis K. Persister cells: molecular mechanisms related to antibiotic tolerance. Handb Exp Pharmacol 2012; 211:121–133 [View Article][PubMed]
    [Google Scholar]
11. Higgins PG, Wisplinghoff H, Krut O, Seifert H. A PCR-based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TU. Clin Microbiol Infect 2007; 13:1199–1201 [View Article][PubMed]
    [Google Scholar]
12. CLSI Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational Supplement. Document M100-S24 Wayne, PA: Clinical and Laboratory Standards Institute; 2014
    [Google Scholar]
13. Gallo SW, Donamore BK, Pagnussatti VE, Ferreira CA, de Oliveira SD. Effects of meropenem exposure in persister cells of Acinetobacter calcoaceticus-baumannii. Future Microbiol 2017; 12:131–140 [View Article][PubMed]
    [Google Scholar]
14. Lechner S, Lewis K, Bertram R. Staphylococcus aureus persisters tolerant to bactericidal antibiotics. J Mol Microbiol Biotechnol 2012; 22:235–244 [View Article][PubMed]
    [Google Scholar]
15. Conlon BP, Nakayasu ES, Fleck LE, Lafleur MD, Isabella VM et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 2013; 503:365–370 [View Article][PubMed]
    [Google Scholar]
16. Hofsteenge N, van Nimwegen E, Silander OK. Quantitative analysis of persister fractions suggested different mechanisms of formation among environmental isolates of E. coli. BMC Microbiol 2013; 13:25 [View Article][PubMed]
    [Google Scholar]
17. Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells. Antimicrob Agents Chemother 2015; 59:4616–4624 [View Article][PubMed]
    [Google Scholar]
18. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science 2004; 305:1622–1625 [View Article][PubMed]
    [Google Scholar]
19. Fleck LE, North EJ, Lee RE, Mulcahy LR, Casadei G et al. A screen for and validation of prodrug antimicrobials. Antimicrob Agents Chemother 2014; 58:1410–1419 [View Article][PubMed]
    [Google Scholar]